Prevention of Surgical Adhesions Using Tyrosine Kinase Inhibitors
Inventors: Mark Puder, Arin Greene
Invention Types: Therapeutics
Research Areas: Internal Medicine, Surgery/Wound Healing
Keywords: Method of Use, SurgeryFor More Information Contact: Khunkhun, Rajinder
Surgeons at Boston Children's Hospital have uncovered a therapeutic technology that minimizes or prevents adhesions, the joining of two normally separate surfaces due to trauma or inflammation, following a surgical procedure. Administration of inhibitors of tyrosine kinase inhibitors such as Sunitinib with surgery in mice and rabbits was observed to inhibit post surgical adhesion formation.
||The present invention also may have tremendous impact on preventing, treating, or minimizing keloid or hypertrophic scars, implant contractures, or scarring after skin incisions.
||Adhesions formed following surgery frequently cause postoperative pain, blockage of intestines, and infertility. Adhesions are the major cause of intestinal obstruction and it is estimated that following an intra-abdominal procedure, adhesions occur in 50 to 80 percent of patients. Intestinal obstruction caused by adhesions leads to prolonged hospital stays, additional abdominal surgery, and even death. Adhesion formation is responsible for up to 30% of infertility cases. The financial burden due to complications of surgical adhesions is $1 billion and account for 846,000 inpatient days annually in the U.S. Adhesion formation is also problematic in extra-abdominal surgeries, such as in the hand, where impediment of movement is frequently troublesome to the patient. The prevention of adhesions would profoundly decrease morbidity, infertility, and reduce health care costs across a broad range of medical disciplines.
General Surgery|Abdominal Surgery|Wound Healing
There are currently no therapeutics available to prevent surgical adhesions. The current standard of care is additional surgery. A small molecule inhibitor for use in this application represents a high margin, large market opportunity, and has the potential to be rapidly adopted as the standard of care.
Key Publications: Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
||Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, Novak K, Flynn E, Heymach JV, Puder M.
||J Surg Res. 2008 Sep;149(1):115-9. Epub 2007 Nov 21.
Related Publications: Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
|Greene AK, Alwayn IP, Nose V, Flynn E, Sampson D, Zurakowski D, Folkman J, Puder M.|Ann Surg. 2005 Jul;242(1):140-6.
IPStatus: Pat. Pend.